HCA Healthcare stock weighs payer pressure against 2027 growth

HCA Healthcare's management used its third-quarter earnings call on Tuesday, October 27, 2026, to outline a resilient operating picture alongside growing reimbursement risks. In the Yahoo Finance transcript, Chief Executive Sam Hazen said demand remained solid, while executives cautioned that payer mix and Medicaid funding would weigh on the 2027 earnings framework.

HCA Healthcare stock traded at 458.95 euros on Lang & Schwarz at 2:13:47 p.m. CET on Thursday, November 5, 2026. Investors can follow the real-time quote of HCA Healthcare stock.

Coverage losses reshape economics

Same-facility equivalent admissions increased 3% year over year in the third quarter, marking HCA Healthcare's 22nd consecutive quarter of volume growth. Admissions rose 2.7% and emergency-room visits gained 5.1%, but inpatient surgeries fell 1.4% and outpatient surgeries declined 3.7% as elective care faced coverage and affordability pressure.

The most significant issue was the migration of patients who lost exchange coverage into uninsured care. Exchange equivalent admissions dropped 19% year over year, while uninsured patients represented 10.5% of total equivalent admissions, compared with 8.5% a year earlier. Management estimated that the payer-mix shift reduced adjusted EBITDA by 400 million US dollars in the quarter.

HCA Healthcare also expects lower Medicaid supplemental-payment benefits in 2027. Management put the reduction at 550 million to 650 million US dollars compared with 2026, largely because some state programs paid in 2026 for services from prior years. The company expects its 2026 Medicaid supplemental-payment benefit to total between 600 million and 800 million US dollars.

Volume growth offsets pressure

Management's preliminary 2027 view calls for 2%-3% volume growth and earnings generally consistent with 2026. Hazen said the company expects fewer people to lose exchange coverage than in 2026, although payer mix should still have a meaningful effect. The company is also relying on its enterprise-wide resiliency program, digital transformation and network development to support cost performance.

HCA Healthcare reaffirmed its 2026 guidance ranges and expects to finish the year in the upper half of those ranges. The company said its cost per equivalent admission, excluding Medicaid supplemental-payment programs, was essentially flat year over year in the third quarter and improved sequentially.

January guidance remains key

The open-enrollment period began on November 1 and runs through mid-January. Management said fourth-quarter exchange volumes and enrollment trends should provide a clearer basis for its detailed 2027 outlook, which is expected with the fourth-quarter earnings call in January.

The broader U.S. equity market remains the relevant backdrop for HCA Healthcare investors, with current S&P 500 market reports.

More news and analyses on HCA Healthcare stock.